MyFinsight
Home
Blog
About
Cash and cash
equivalents
$427,740K
(20.89%↑ Y/Y)
Short-term investments
$417,891K
(27.34%↑ Y/Y)
Accounts receivable, net
$138,662K
(24.43%↑ Y/Y)
Inventory
$45,556K
(46.76%↑ Y/Y)
Prepaid taxes
$15,308K
Prepaid expenses and
other current assets
$14,491K
(-14.16%↓ Y/Y)
Total current assets
$1,059,648K
(25.95%↑ Y/Y)
Long-term investments
$257,291K
(85.36%↑ Y/Y)
Property and equipment,
net
$153,775K
(2.25%↑ Y/Y)
Deferred tax asset, net of
valuation allowance
$22,824K
Right-of-use assets
$6,826K
(-10.83%↓ Y/Y)
Other non-current
assets
$284K
(44.16%↑ Y/Y)
Total assets
$1,500,648K
(31.82%↑ Y/Y)
Total liabilities and
stockholders equity
$1,500,648K
(31.82%↑ Y/Y)
Total stockholders
equity
$1,359,126K
(30.60%↑ Y/Y)
Total liabilities
$141,522K
(44.78%↑ Y/Y)
Accumulated other
comprehensive (loss) gain
-$4,335K
(-474.68%↓ Y/Y)
Additional paid-in capital
$1,228,598K
(7.20%↑ Y/Y)
Retained earnings
$134,863K
(226.51%↑ Y/Y)
Total current
liabilities
$127,397K
(46.61%↑ Y/Y)
Other long-term
liabilities
$7,080K
(154.04%↑ Y/Y)
Lease liability
$7,045K
(-12.64%↓ Y/Y)
Accrued rebates
$83,480K
(61.66%↑ Y/Y)
Accrued expenses and
other current...
$35,565K
(34.12%↑ Y/Y)
Accounts payable
$6,544K
(-8.14%↓ Y/Y)
Current portion of lease
liability
$1,808K
(11.81%↑ Y/Y)
Back
Back
Balance Sheet
Krystal Biotech, Inc. (KRYS)
Krystal Biotech, Inc. (KRYS)
source: myfinsight.com